文献速递胸部肿瘤

德国国家基因组医学网络肺癌项目(nNGM)中非典型EGFR突变的治疗结局

Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM).
PubMed 文献 · Ann Oncol · 2022-03-06

这项回顾性多中心研究纳入德国nNGM网络中856例携带非典型EGFR突变的NSCLC病例,其中260例有系统性治疗后的随访数据。研究验证了EGFR-TKI在不常见突变组疗效优于化疗,而exon 20插入多对EGFR-TKI不敏感;极罕见点突变及复合突变中对TKI的敏感性高度异质。作者据此提出新的nNGM非典型EGFR突变分类。

要点

  • 不常见突变组(G719X、S768I、L861Q及组合)中EGFR-TKI疗效优于化疗。
  • exon 20插入组多数对EGFR-TKI不敏感。
  • 极罕见点突变及含exon 19缺失或L858R的复合突变显示TKI敏感性,但组内反应高度异质。

核心结论

  • 作者基于研究结果提出新的nNGM非典型EGFR突变分类。

研究设计与样本

  • 德国国家基因组医学网络(nNGM)的回顾性多中心研究,12个中心报告856例携带非典型EGFR突变(含共存突变)的NSCLC病例。
  • 其中260例有接受不同EGFR-TKI、化疗和免疫检查点抑制剂治疗后的临床随访数据。
  • 按三类分析治疗反应:不常见突变(G719X、S768I、L861Q及组合)、exon 20插入、极罕见EGFR突变(极罕见单点突变、复合突变、exon 18缺失、exon 19插入)。

主要发现

  • 研究包含迄今报告最大的接受不同系统性治疗的极罕见EGFR单点突变和复合突变真实世界队列。
  • 在不常见突变组中验证了EGFR-TKI疗效高于化疗,而多数exon 20插入对EGFR-TKI不敏感。
  • 发现极罕见点突变以及含exon 19缺失或L858R的复合EGFR突变对TKI敏感,与组合伙伴无关。
  • 极罕见突变组的治疗反应高度异质。
  • 共存TP53突变对exon 20插入组和极罕见突变组中接受EGFR-TKI治疗患者的结局呈非显著的不利趋势,而不常见突变组无此趋势。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Atypical EGFR mutations occur in 10%-30% of non-small-cell lung cancer (NSCLC) patients with EGFR mutations and their sensitivity to classical epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKI) is highly heterogeneous. Patients harboring one group of uncommon, recurrent EGFR mutations (G719X, S768I, L861Q) respond to EGFR-TKI. Exon 20 insertions are mostly insensitive to EGFR-TKI but display sensitivity to exon 20 inhibitors. Clinical outcome data of patients with very rare point and compound mutations upon systemic treatments are still sparse to date. PATIENTS AND METHODS: In this retrospective, multicenter study of the national Network Genomic Medicine (nNGM) in Germany, 856 NSCLC cases with atypical EGFR mutations including co-occurring mutations were reported from 12 centers. Clinical follow-up data after treatment with different EGFR-TKIs, chemotherapy and immune checkpoint inhibitors were available from 260 patients. Response to treatment was analyzed in three major groups: (i) uncommon mutations (G719X, S7681, L861Q and combinations), (ii) exon 20 insertions and (iii) very rare EGFR mutations (very rare single point mutations, compound mutations, exon 18 deletions, exon 19 insertions). RESULTS: Our study comprises the largest thus far reported real-world cohort of very rare EGFR single point and compound mutations treated with different systemic treatments. We validated higher efficacy of EGFR-TKI in comparison to chemotherapy in group 1 (uncommon), while most exon 20 insertions (group 2) were not EGFR-TKI responsive. In addition, we found TKI sensitivity of very rare point mutations (group 3) and of complex EGFR mutations containing exon 19 deletions or L858R mutations independent of the combination partner. Notably, treatment responses in group 3 (very rare) were highly heterogeneous. Co-occurring TP53 mutations exerted a non-significant trend for a detrimental effect on outcome in EGFR-TKI-treated patients in groups 2 and 3 but not in group 1. CONCLUSIONS: Based on our findings, we propose a novel nNGM classification of atypical EGFR mutations.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Janning M, Süptitz J, Albers-Leischner C, et al. Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM). Ann Oncol. 2022. PMID: 35263633. doi:10.1016/j.annonc.2022.02.225

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。